文献速递慢性肾脏病遗传性与小管间质肾病

尿液生物标志物识别高风险进展的常染色体显性多囊肾病患者

Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression.
PubMed 文献 · Kidney Int Rep · 2017-10-14

本研究纳入104例ADPKD患者,测量24小时尿中炎症、肾小球和肾小管损伤标志物,分析其与eGFR、mGFR年变化及htTKV变化的关联。发现尿β2MG和MCP-1与eGFR年下降独立相关,且加入常规风险标志物模型后显著提升预测效能(R2从0.152增至0.292,P=0.001)。

要点

  • 尿β2MG和MCP-1与ADPKD患者eGFR年下降独立相关。
  • 在常规风险标志物基础上加入β2MG和MCP-1可显著改善eGFR下降预测。
  • 尿β2MG和MCP-1有望成为ADPKD进展的预测工具。

核心结论

  • 尿β2MG和MCP-1排泄与ADPKD患者GFR下降相关,且超越常规风险标志物的预测价值。

研究设计与样本

  • 在104例ADPKD患者基线时测量24小时尿中炎症、肾小球和肾小管损伤标志物。
  • 疾病进展以eGFR年变化、mGFR年变化或htTKV年变化表示。
  • 采用多变量线性回归评估标志物与进展的关联,并校正常规风险标志物。

主要发现

  • β2MG与eGFR年变化独立相关(标准化β=-0.35,P=0.001)。
  • MCP-1与eGFR年变化独立相关(标准化β=-0.29,P=0.009)。
  • 将β2MG和MCP-1加入常规风险标志物模型后,R2从0.152升至0.292(P=0.001)。
  • 仅在eGFR≥60 ml/min per 1.73 m2患者中或研究mGFR变化时,结果基本相似。
  • 与htTKV变化的关联较弱。

关键数值与推荐

  • 尿β2MG和MCP-1与eGFR年变化独立相关。
  • 加入β2MG和MCP-1后模型R2从0.152增至0.292(P=0.001)。

临床怎么用

  • 尿β2MG和MCP-1或可作为ADPKD疾病进展的预测工具,辅助识别高风险患者。

局限性

  • 与htTKV变化的关联较弱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The variable disease course of autosomal dominant polycystic kidney disease (ADPKD) makes it important to develop biomarkers that can predict disease progression, from a patient perspective and to select patients for renoprotective treatment. We therefore investigated whether easy-to-measure urinary biomarkers are associated with disease progression and have additional value over that of conventional risk markers. METHODS: At baseline, inflammatory, glomerular, and tubular damage markers were measured in 24-hour urine collections (albumin, IgG, kidney injury molecule-1 (KIM-1), N-acetyl-β-d-glucosaminidase (NAG), β2 microglobulin (β2MG), heart-type fatty acid binding protein (HFABP), macrophage migration inhibitory factor (MIF), neutrophil gelatinase-associated lipocalin (NGAL), and monocyte chemotactic protein-1 (MCP-1). Disease progression was expressed as annual change in estimated glomerular filtration rate (eGFR, Chronic Kidney Disease EPIdemiology equation), measured glomerular filtation rate (mGFR, using 125I-iothalamate), or height-adjusted total kidney volume (htTKV). Multivariable linear regression was used to assess associations of these markers independent of conventional risk markers. RESULTS: A total of 104 ADPKD patients were included (40 ± 11 years, 39% female, eGFR 77 ± 30, mGFR 79 ± 30 ml/min per 1.73 m2 and htTKV 852 [510-1244] ml/m). In particular, β2MG and MCP-1 were associated with annual change in eGFR, and remained associated after adjustment for conventional risk markers (standardized β = -0.35, P = 0.001, and standardized β = -0.29, P = 0.009, respectively). Adding β2MG and MCP-1 to a model containing conventional risk markers that explained annual change in eGFR significantly increased the performance of the model (final R2 = 0.152 vs. 0.292, P = 0.001). Essentially similar results were obtained when only patients with an eGFR ≥ 60 ml/min per 1.73 m2 were selected, or when change in mGFR was studied. Associations with change in htTKV were less strong. CONCLUSION: Urinary β2MG and MCP-1 excretion were both associated with GFR decline in ADPKD, and had added value beyond that of conventional risk markers. These markers therefore have the potential to serve as predictive tools for clinical practice.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Messchendorp AL, Meijer E, Boertien WE, et al. Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression. Kidney Int Rep. 2017. PMID: 29725632. doi:10.1016/j.ekir.2017.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。